Daniel Wendling
French Institute of Health and Medical Research
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Daniel Wendling.
Clinical Epigenetics | 2010
Georges Herbein; Daniel Wendling
Chromatin remodeling and gene expression are regulated by histone deacetylases (HDACs) that condense the chromatin structure by deacetylating histones. HDACs comprise a group of enzymes that are responsible for the regulation of both cellular and viral genes at the transcriptional level. In mammals, a total of 18 HDACs have been identified and grouped into four classes, i.e., class I (HDACs 1, 2, 3, 8), class II (HDACs 4, 5, 6, 7, 9, 10), class III (Sirt1–Sirt7), and class IV (HDAC11). We review here the role of HDACs on viral replication and how HDAC inhibitors could potentially be used as new therapeutic tools in several viral infections.
MT. Médecine thérapeutique | 2007
Daniel Wendling; Pascal Claudepierre; Eric Toussirot; Gérald Streit; Clément Prati; Paul Ornetti
Les agents anti-TNFα ont demontre une efficacite clinique sans egal jusqu’alors dans la spondylarthrite, ayant conduit a l’obtention d’une AMM dans cette indication. La tolerance et les precautions d’utilisation sont identiques a celles des autres indications de ces agents biologiques. L’efficacite se manifeste sur tous les aspects cliniques de la maladie, les parametres de l’inflammation biologique et IRM. Cependant, l’effet structural radiologique n’est pas formellement demontre a ce jour. Certains facteurs predictifs de bonne reponse sont identifies, en particulier une CRP elevee a l’inclusion. Certaines questions concernant l’utilisation en pratique restent ouvertes et justifient des etudes complementaires.
Arthritis Research & Therapy | 2001
Denis Reviron; Aleth Perdriger; Eric Toussirot; Daniel Wendling; Nathalie Balandraud; Sandrine Guis; Gilbert Semana; Pierre Tiberghien; Pierre Mercier; Jean Roudier
We propose to classify HLA-DRB1 alleles into 3 groups: shared epitope positive (SE), shared epitope negative with a positively charged HLA-DR P4 pocket (XP4p) and shared epitope negative with a negative or neutral HLA-DR XP4 pocket (XP4n). Using this classification to analyse 3 different French populations, we find that: -SE/SE or SE/XP4p genotypes are associated with a high risk to develop RA. -XP4p/XP4p or SE/XP4n genotypes are neutral -XP4p/XP4p or XP4n/XP4n genotypes are protective with respect to the development of RA.
/data/revues/1297319X/00730006/06001886/ | 2007
Daniel Wendling; Eric Toussirot; Gérald Streit; Clément Prati
/data/revues/1297319X/00750005/08001401/ | 2008
Daniel Wendling; Jean-Pierre Cedoz; Evelyne Racadot
Arthritis Research & Therapy | 2003
Eric Toussirot; Daniel Wendling; J. Luka; Pierre Tiberghien; Jean Roudier
/data/revues/1297319X/v75sS1/S1297319X08736200/ | 2008
Thao Pham; Bruno Fautrel; Jacques-Eric Gottenberg; Philippe Goupille; Eric Hachulla; Charles Masson; Jacques Morel; Luc Mouthon; Alain Saraux; Thierry Schaeverbeke; Daniel Wendling; Xavier Mariette; Jean Sibilia
Archive | 2010
Daniel Wendling; Clément Prati; Eric Toussirot; Paul Ornetti
Archive | 2017
Xavier Mariette; Paul Seror; Aleth Perdriger; Daniel Wendling; Denis Mulleman; Edouard Pertuiset; Antoine Martin; Sylvie Melac-Ducamp; Michel Alcalay
/data/revues/1297319X/v85i1/S1297319X17300015/ | 2017
Maxime Sondag; Frank Verhoeven; Xavier Guillot; Clément Prati; Charline Briot; Lucine Vuitton; Stéphane Koch; Daniel Wendling